B7-H3 in Cancer Immunotherapy—Prospects and Challenges: A Review of the Literature
In today’s oncology, immunotherapy arises as a potent complement for conventional cancer treatment, allowing for obtaining better patient outcomes. B7-H3 (CD276) is a member of the B7 protein family, which emerged as an attractive target for the treatment of various tumors. The molecule modulates an...
Saved in:
| Main Authors: | Sylwia Mielcarska, Anna Kot, Miriam Dawidowicz, Agnieszka Kula, Piotr Sobków, Daria Kłaczka, Dariusz Waniczek, Elżbieta Świętochowska |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-08-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/14/15/1209 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
B7H3 in Gastrointestinal Tumors: Role in Immune Modulation and Cancer Progression: A Review of the Literature
by: Sylwia Mielcarska, et al.
Published: (2025-04-01) -
Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer
by: Qi Shen, et al.
Published: (2024-12-01) -
Tumor Immunotherapy Targeting B7-H3: From Mechanisms to Clinical Applications
by: Guo Y, et al.
Published: (2025-03-01) -
B7-H3 in glioblastoma and beyond: significance and therapeutic strategies
by: Davor Babič, et al.
Published: (2024-11-01) -
From tumor immunity to precision medicine: the next step in B7-H3/CD276 research
by: Fang Haolie, et al.
Published: (2025-03-01)